Endocrine tumours of the pancreas

Verbeke, Caroline

doi:10.1111/j.1365-2559.2010.03490.x

Cited by 48 publications

(24 citation statements)

References 101 publications

(193 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[14] In our study it accounted for 11.1% of the cases, these neoplasms were encapsulated with grey white appearance and areas of haemorrhage. One of the case showed predominant vascular proliferation with areas of haemorrhage.…”

Section: Discussionsupporting

confidence: 45%

A tertiary care centre experience with periampullary and pancreatic neoplasm in pylorus preserving pancreaticoduodenectomy specimens

Mohandas¹,

Vasudevan²,

Kv³

2017

APALM

View full text Add to dashboard Cite

Inclusion Criteria: Cases with suspected pancreatic/ periampullary cancer that were assumed to be resectable according to preoperative diagnostic work up were included.Exclusion Criteria: Patients with distant metastasis or locally unresectable tumors, as indicated by preoperative workup and intraoperative findings were excluded.Pathologic Review: Specimens were dissected according to CAP protocol. Primary Pathology and extent of the disease were determined on gross and microscopic examination. TNM staging was done. Resection margins of the specimens were inked with Indian ink and considered positive if the neoplasm was present at the neck, uncinate processus, CBD, Duodeum/gastric resection, SMA, SMV and retroperitoneal margin.Statistical Analysis: All variables were entered in excel sheet and analysed by SPSS16. P value was obtained in few variables. Results: In the present study, females predominated M:F of 1:3.5. The median age for the malignant lesions ranged from 55 yrs to 60yrs and for benign lesions were 30-39years. The most common clinical presentation were neoplastic lesions accounted for 80% of the total lesions and non neoplastic lesions such as chronic calcific pancreatitis for 20%. Pancreatic adenocarcinoma accounted for most number of lesions. Tumor variables such as perineural invasion and margin status positivitiy were seen in pancreatic carcinomas.

show abstract

Section: Discussionsupporting

confidence: 45%

A tertiary care centre experience with periampullary and pancreatic neoplasm in pylorus preserving pancreaticoduodenectomy specimens

Mohandas¹,

Vasudevan²,

Kv³

2017

APALM

View full text Add to dashboard Cite

show abstract

“…PNETs represent a subset of pancreatic tumors (<3%) that vary in clinical appearance and biological behavior, ranging from benign to highly malignant [6]. However, although the WHO classification describes the classic pathologic features, little is known about molecular determinants that could predict the status of the tumor [26].…”

Section: Discussionmentioning

confidence: 99%

“…E-mail: mtachezy@ uke.uni-hamburg.de. a predictive system for the biological behavior of this rare tumor entity [6]. Further characterization of each tumor is needed, identifying patients who might benefit from individually tailored adjuvant or specific surgical treatment.…”

Section: Introductionmentioning

confidence: 99%

ALCAM (CD166) Expression as Novel Prognostic Biomarker for Pancreatic Neuroendocrine Tumor Patients

Tachezy

Zander

Marx

et al. 2011

Journal of Surgical Research

View full text Add to dashboard Cite

“…Finally, the cytologic examination of biopsied tumor can aid the characterization of a tumor as a well-differentiated endocrine tumor (low grade of malignancy), a well-differentiated endocrine carcinoma (intermediate grade), or a poorly differentiated endocrine carcinoma (high grade). This characterization predicts PNET behavior [77][78][79].…”

Section: Diagnostic Tools and Biomarkersmentioning

confidence: 71%

Pancreatic neuroendocrine tumors

Karakaxas¹,

Gazouli²,

Liakakos³

et al. 2014

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Pancreatic neuroendocrine tumors (PNETs) share a unique genetic identity, functional behavior, and clinical course. Compared with tumors of the exocrine pancreas, they are rare and show a different biologic behavior and prognosis. On the basis of data from recent studies, all PNETs, outside of small insulinomas, should be considered potentially malignant and treated accordingly. Untreated tumors have a high possibility to grow locally into adjacent structures or spread to distant organs. Although surgical excision irrespective of tumor functioning or nonfunctioning state remains the cornerstone of therapy, providing the best disease-free and survival rates to date, the understanding of the genetic nature of the disease yields new 'targets' to consider in drug development. The aim of this review is to summarize all recent advances of genetic research and new drug development in terms of PNETs, especially their genetic identity and subsequent alterations leading to the development of near or total malignant activity, and the new medical treatment strategies of this potentially curable disease on the basis of therapeutical agents acting, where possible, at the genetic level.

show abstract

Endocrine tumours of the pancreas

Cited by 48 publications

References 101 publications

A tertiary care centre experience with periampullary and pancreatic neoplasm in pylorus preserving pancreaticoduodenectomy specimens

A tertiary care centre experience with periampullary and pancreatic neoplasm in pylorus preserving pancreaticoduodenectomy specimens

ALCAM (CD166) Expression as Novel Prognostic Biomarker for Pancreatic Neuroendocrine Tumor Patients

Pancreatic neuroendocrine tumors

Contact Info

Product

Resources

About